In what has been billed as landmark ruling the Intellectual Property Appellate Board upheld the country’s first compulsory licence to NATCO Pharma for Bayer’s cancer drug Nexavar recently. In layman language, NATCO, an Indian pharmaceutical company had been the given the right to copy and sell
March 14 2013, 7:14 pm
Read MoreThat the compulsory licence verdict in favour of NATCO Pharma would change the landscape of the pharma industries the world over was never in doubt. The verdict was hailed as ‘revolutionary’, ‘path-breaking’ and hailed as ‘a triumph for humanity’ by NATCO CFO and director P Bhaskara
March 19 2013, 11:12 am
Read MoreCompulsory licences are here to stay. The Intellectual Property Appellate Board (IPAB) on Monday upheld the country’s first compulsory licence to the Hyderabad based NATCO Pharma for Bayer’s cancer drug Nexavar setting a legal precedent and paving the way for more companies to challenge
March 5 2013, 8:41 am
Read MoreDespite the ruling earlier this week that allowed Natco, an Indian pharmacy to copy Bayer’s Nexavar, a blockbuster cancer drug that will bring down the price by 97%, the generic cancer drug is still too costly for most people. The generic version of the drug, German drug-maker Bayer's
April 23 2013, 4:46 pm
Read MoreOver the post-independence years India has launched several health programs. In this article we highlight a few such programs that have improved or have the potential to improve the health of India’s populace. National Rural Health Mission (NRHM), Ministry of Health and Family Welfare “Health
October 3 2012, 10:52 am
Read More